Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
The Medical Department, 3D Medicines Inc., Shanghai, China.
Front Immunol. 2021 Dec 24;12:799822. doi: 10.3389/fimmu.2021.799822. eCollection 2021.
Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer with a poor prognosis. Recently, an immunotherapy strategy represented by programmed cell death 1 (PD-1) inhibitors has been applied to the systemic treatment of advanced iCCA. However, immunotherapy combined with chemotherapy as first-line maintenance therapy was rarely reported. Our report presented an advanced iCCA patient who had a dramatic response to the PD-1 inhibitor sintilimab combined with gemcitabine plus cisplatin as the first-line therapy and sintilimab combined with capecitabine as maintenance therapy, yielding an ongoing progression-free survival of 16 months.
肝内胆管癌（iCCA）是第二常见的原发性肝癌，预后不良。最近，以程序性细胞死亡 1（PD-1）抑制剂为代表的免疫治疗策略已被应用于晚期 iCCA 的系统治疗。然而，免疫治疗联合化疗作为一线维持治疗的报道很少。我们报告了一例晚期 iCCA 患者，他对 PD-1 抑制剂信迪利单抗联合吉西他滨加顺铂作为一线治疗以及信迪利单抗联合卡培他滨作为维持治疗有显著反应，无进展生存期持续 16 个月。
